2	O
-	O
methoxyestradiol	O
inhibits	O
hypoxia	O
-	O
inducible	O
factor	O
1alpha	O
,	O
tumor	B-Cancer
growth	O
,	O
and	O
angiogenesis	O
and	O
augments	O
paclitaxel	O
efficacy	O
in	O
head	B-Cancer
and	I-Cancer
neck	I-Cancer
squamous	I-Cancer
cell	I-Cancer
carcinoma	I-Cancer
.	O

PURPOSE	O
:	O
Head	B-Cancer
and	I-Cancer
neck	I-Cancer
squamous	I-Cancer
cell	I-Cancer
carcinomas	I-Cancer
have	O
been	O
reported	O
to	O
overexpress	O
hypoxia	O
-	O
inducible	O
factor	O
(	O
HIF	O
)	O
-	O
1alpha	O
,	O
a	O
transcription	O
factor	O
that	O
promotes	O
expression	O
of	O
angiogenesis	O
factors	O
and	O
resistance	O
to	O
programmed	O
and	O
therapy	O
-	O
induced	O
cell	B-Cell
death	O
.	O

2	O
-	O
Methoxyestradiol	O
(	O
2ME2	O
)	O
is	O
a	O
natural	O
compound	O
with	O
HIF	O
-	O
1alpha	O
inhibitory	O
activity	O
that	O
is	O
currently	O
being	O
evaluated	O
in	O
phase	O
1	O
and	O
2	O
clinical	O
trials	O
for	O
advanced	O
solid	B-Cancer
tumors	I-Cancer
and	O
multiple	O
myeloma	B-Cancer
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
study	O
to	O
evaluate	O
the	O
effects	O
of	O
2ME2	O
in	O
head	B-Cancer
and	I-Cancer
neck	I-Cancer
squamous	I-Cancer
cell	I-Cancer
carcinoma	I-Cancer
.	O

EXPERIMENTAL	O
DESIGN	O
:	O
In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
2ME2	O
alone	O
and	O
in	O
combination	O
with	O
paclitaxel	O
,	O
an	O
active	O
agent	O
in	O
recurrent	O
or	O
advanced	O
head	B-Cancer
and	I-Cancer
neck	I-Cancer
squamous	I-Cancer
cell	I-Cancer
carcinoma	I-Cancer
.	O

RESULTS	O
:	O
2ME2	O
exhibited	O
antiproliferative	O
and	O
cytotoxic	O
effects	O
in	O
a	O
panel	O
of	O
five	O
head	B-Cell
and	I-Cell
neck	I-Cell
squamous	I-Cell
cell	I-Cell
carcinoma	I-Cell
cell	I-Cell
lines	I-Cell
in	O
the	O
0	O
.	O
5	O
to	O
10	O
micromol	O
/	O
L	O
range	O
,	O
including	O
induction	O
of	O
G2	O
-	O
M	O
blockade	O
,	O
caspase	O
-	O
3	O
/	O
7	O
activation	O
,	O
and	O
apoptosis	O
at	O
48	O
hours	O
.	O

2ME2	O
resulted	O
in	O
decreased	O
nuclear	B-Cellular_component
HIF	O
-	O
1alpha	O
-	O
binding	O
activity	O
and	O
affected	O
the	O
expression	O
of	O
downstream	O
genes	O
,	O
such	O
as	O
bid	O
,	O
a	O
proapoptotic	O
bcl	O
-	O
2	O
family	O
member	O
,	O
and	O
vascular	O
endothelial	O
growth	O
factor	O
,	O
a	O
proangiogenic	O
cytokine	O
.	O

The	O
up	O
-	O
regulation	O
of	O
Bid	O
(	O
57	O
.	O
5	O
%	O
at	O
12	O
hours	O
,	O
P	O
less	O
than	O
0	O
.	O
0006	O
)	O
and	O
inhibition	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
secretion	O
(	O
57	O
.	O
7	O
%	O
at	O
24	O
hours	O
,	O
P	O
less	O
than	O
0	O
.	O
015	O
;	O
and	O
50	O
.	O
3	O
%	O
at	O
48	O
hours	O
,	O
P	O
less	O
than	O
0	O
.	O
0006	O
)	O
could	O
be	O
partially	O
attributed	O
to	O
the	O
effects	O
on	O
HIF	O
-	O
1alpha	O
,	O
because	O
HIF	O
-	O
1alpha	O
small	O
interfering	O
RNAs	O
produced	O
similar	O
effects	O
.	O

Finally	O
,	O
in	O
vivo	O
,	O
in	O
a	O
xenograft	B-Cancer
model	O
of	O
head	B-Cancer
and	I-Cancer
neck	I-Cancer
squamous	I-Cancer
cell	I-Cancer
carcinoma	I-Cancer
using	O
UM	B-Cell
-	I-Cell
SCC	I-Cell
-	I-Cell
11A	I-Cell
cells	I-Cell
,	O
2ME2	O
exhibited	O
antitumor	B-Cancer
and	O
antiangiogenic	O
activity	O
,	O
as	O
measured	O
by	O
CD31	O
immunostaining	O
.	O

CONCLUSIONS	O
:	O
These	O
results	O
provide	O
support	O
for	O
the	O
use	O
of	O
2ME2	O
in	O
combination	O
with	O
paclitaxel	O
for	O
the	O
treatment	O
of	O
recurrent	O
or	O
advanced	O
head	B-Cancer
and	I-Cancer
neck	I-Cancer
squamous	I-Cancer
cell	I-Cancer
carcinoma	I-Cancer
.	O

